# AZD7268 Safety and Tolerability Study

> **NCT01020799** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 247 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** AZD7268
- **DRUG:** Escitalopram
- **DRUG:** Placebo capsules
- **DRUG:** Placebo tablets

## Key facts

- **NCT ID:** NCT01020799
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2012-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01020799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01020799, "AZD7268 Safety and Tolerability Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01020799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*